Perspectives on pharmaceutical manufacturing, capacity planning, and simulation-driven operations.
Mexico is attracting billions in pharma investment, but nearshoring without capacity intelligence creates expensive failures. Here's what manufacturers actually need before expanding south.
Architects design beautiful clean rooms that underperform by 40%. The missing link: capacity simulation before the first blueprint. Here's why facility builders need it.
Pharma companies are spending $300B on expansion, but most fail at capacity planning. Why adding facilities reduces efficiency — and how to expand right.
Get insights on pharmaceutical capacity planning and simulation-driven operations delivered to your inbox.
We respect your privacy. Unsubscribe anytime.
Regulatory approval is just 10% of biosimilar success. Scaling to meet market demand is where most projects fail — learn how to avoid the capacity trap.
Adding 40% more manufacturing assets can cut effective capacity by 20%. Learn why multi-country pharma expansions often lose output despite more plants.
Stop buying equipment first. The three-phase approach — operational levers, lot optimization, then capex — solves pharma capacity gaps at a fraction of cost.
A LATAM pharma manufacturer faced 385% granulation utilization by 2032. We redesigned into 5 dedicated routes, cutting batches 67% — all under 80% load.
$3.2M on a new tablet press expecting 30% more capacity. Result: 8%. Network effects in pharma mean adding equipment shifts the bottleneck, not fixes it.
"One machine for everything" sounds efficient — until changeovers eat 30% of capacity. Why dedicated routes beat pooled equipment in multi-product pharma.
Construction changes cost 10-50x more than design changes. Capacity simulation before the first drawing prevents overbuilt cleanrooms and undersized areas.
Spreadsheets can't model variability or resource interactions. Monte Carlo simulation runs thousands of scenarios to reveal bottlenecks before they hit.